socalTECH

APRIL 29, 2021

Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.

Westlake Village 113

Westlake Village Thousand Oaks Funding CalTech 113

socalTECH

JANUARY 4, 2021

Thousand Oaks-based Teledyne Technologies said today that it has agreed to acquire FLIR Systems, which develops infrared cameras and similar technology, in a deal worth $8.0 Both companies develops sensors, cameras, and sensor systems. Both companies develops sensors, cameras, and sensor systems.

Thousand Oaks 113

Thousand Oaks Funding Technology Develop 113

socalTECH

NOVEMBER 1, 2012

Thousand Oaks-based Amgen and venture firm Kleiner Perkins Caufield & Byers have put their backing behind a new, Westlake Village based drug development firm, Atara Biotherapeutics , in an unusual spinout of technology from the biotech giant. Financial details of the funding were not announced.

Thousand Oaks 147

Thousand Oaks Westlake Village Funding Technology 147

socalTECH

DECEMBER 27, 2019

Every year, at the end of the year, we share some reflections on the past year from our readers, entrepreneurs, venture capitalists, sponsors, and others in the local technology community. Many jobs have been created and companies have received funding through our efforts of supporting and bringing value to founders.

Startup 196

Startup Thousand Oaks Mentor Ventura 196

socalTECH

NOVEMBER 7, 2013

Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group.

Thousand Oaks 164

Thousand Oaks UCLA Venture Capital Equity 164

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M Akriveia Therapeutics said it is developing immunotherapeutic products that are specifically activated in the microenvironment of the tumor. in a Series A investment. READ MORE>>.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

OCTOBER 9, 2015

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. In addition to Amgen, Adheron has received venture capital from Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, and SROne.

Thousand Oaks 100

Thousand Oaks Venture Capital Activity Capital 100